Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
31 hedge funds and large institutions have $1.55M invested in Statera Biopharma, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
11% less funds holding
Funds holding: 35 → 31 (-4)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
53% less capital invested
Capital invested by funds: $3.32M → $1.55M (-$1.77M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.7K |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$8.76K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$2.92K |
| 4 |
Morgan Stanley
New York
|
+$584 |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$549 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$888K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$89K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$24K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$17.8K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$17K |
STAB Hedge Fund Activity: Q2 2014 in Review
31 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2014, worth a combined $1.55M — down 53% from $3.32M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of STAB and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $19.7K. The largest seller was Sabby Management, cutting an estimated $888K.
- 31 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2014, down from 35 in Q1 2014.
- Funds reported $1.55M of Statera Biopharma, Inc. Common Stock stock for Q2 2014, down 53% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2014 and 6 closed out, a net change of -4 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2014 was Vanguard Group, an estimated $19.7K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2014 was Sabby Management, an estimated $888K sold.
Based on aggregated 13F filings for Q2 2014.